Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.47 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.44 |
| ▸ | BMP1 | P13497 | 2/20 | 0.44 |
| ▸ | GNPAT | O15228 | 2/20 | 0.42 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21440833 | 0.89 | NOD1 (0.53) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL21440846 | 0.89 | NOD1 (0.53) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL21242721 | 0.89 | NOD1 (0.53) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL13377667 | 0.89 | NOD1 (0.53) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL12118226 | 0.89 | NOD1 (0.53) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL21242989 | 0.89 | NOD1 (0.53) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL19619057 | 0.88 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL18271261 | 0.88 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL14169172 | 0.88 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL22315435 | 0.85 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLABMP1GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2021195401-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | HAVCR2, ACE2, EPCAM | FOLH1 1276/4885NAALAD2 1571/4885RIMKLA 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.